French National Plans against hepatitis B and C ... and the way forward

Françoise Roudot-Thoraval
Department of Public Health
Hôpital Henri Mondor – Université Paris Est Créteil

VHPB, Antwerp Nov 14th 2014
HCV/HBV studies and responses: Timeline

1st national seroprevalence survey

Episodes of transmission in health-care settings

High prevalence in DUs

1994

1996

1999

2002

2004

2009

1st national Plan (HCV)

2nd national Plan (HCV+HBV)

Law relative to public health policy

3rd national Plan (HCV+HBV)

Conference on Hep C treatment

Surveillance

• National seroprevalence survey in DUs

• 2nd national seroprevalence survey + HBV

Implementation of hepatology reference centres

VHPB, Antwerp Nov 14th 2014
The French National Plan 2009-2012

1. Reduction of HBV and HCV transmission, and increase of HBV immunization
   4 objectives – 17 actions

2. Stepping up hepatitis B and C identification
   2 objectives – 6 actions

3. Improvement of access to care and quality of life of patients
   4 objectives – 11 actions

4. Special measures adapted to prison milieu
   1 objective – 5 actions

5. Surveillance and evaluation, research forecasting
   4 objectives – 16 actions
Objectives of the national plan

1. Reduction of HBV and HCV transmission
   • Intensify information and communication about hepatitis
   • Increase HBV vaccine coverage
   • Reinforce harm reduction in IVDU
   • Improve risk prevention in care settings

2. Stepping up hepatitis B and C screening
   – Set up the conditions of a better access to screening of people at risk
   – Improve the practice of testing and counselling

3. Improvement of access to care and quality of life of patients
   – Improve management of HCV treatment
   – Encourage therapeutic education
   – Support actions in collaboration with reference centers, patients associations

4. Special measures adapted to prison milieu
   – Concerning harm reduction programmes, screening and access to treatment

5. Surveillance and evaluation – research forecasting
   – Improve surveillance and epidemiological knowledge
   – Develop research and forecasting
   – Follow-up and evaluation of the national plan

Zagreb, February 1st 2013

VHPB, Antwerp Nov 14th 2014
What has been done?

- Prevention
- Screening
- Treatment
- Research
HBV prevention: Rate of HBV coverage in infants

Reimbursement of the hexavalent vaccine

1 dose (6 months)
3 doses (24 months)

Year of birth

Screening – link to care

• High activity of screening
  – 3.4 millions HCV Elisa tests per year
    • Incidence of new diagnoses: 1/10 000 to 1/1 000 according to the region
  – 3.4 millions HBs Ag tests per year
    • Incidence of new diagnoses: 1/10 000 to 1/1 000 according to the region
• Proportion aware of their infection
  
<table>
<thead>
<tr>
<th>Year</th>
<th>HCV</th>
<th>HBV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>24%</td>
<td>46%</td>
</tr>
<tr>
<td>2004</td>
<td>56%</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>65%</td>
<td></td>
</tr>
</tbody>
</table>

VHPB, Antwerp Nov 14th 2014
Screening – link to care

- **HCV**
  - Infected patients (2004)  240,000
  - Naïve treated patients (up to 2014)  70,000
  - Cured patients  35,000
    - (dead  15,000)
  - Residual infected patients  190,000

<table>
<thead>
<tr>
<th>Screened</th>
<th>To be screened</th>
</tr>
</thead>
<tbody>
<tr>
<td>120,000</td>
<td>70,000</td>
</tr>
</tbody>
</table>

- Proposal: to treat 15,000 patients per year with DAAs
- (14,000 have been treated in 2014)
Research

• Epidemiological
  – Modeling HCV epidemiology
  – Cost-effectiveness studies

• Therapeutic
  – Study « CUPIC »
  – Cohort « HEPATHER »
    • More than 2000 patients included and treated with new DAAs to study efficacy and safety in real life
Impact of new treatments on HCV epidemiology in France

Prevalence: - 68,000
Mortality avoided: 8100
Cirrhoses avoided: 8200

Leleu H et al, AASLD 2013
Research

• Epidemiological
  – Modeling HCV epidemiology
  – Cost-effectiveness studies

• Therapeutic
  – Study « CUPIC »
  – Cohort « HEPATHER »
    • More than 2000 patients included and treated with new DAAs to study efficacy and safety in the real life
The way forward

• Guidelines for the management of patients with HBV or HCV
  – Report = « state of the art » in 2013-14
  – Guidelines and recommendations (180)
  – Creation of a follow-up committee
    • In charge of priorization of actions
    • Think at implementation strategies for their achievement
    • Follow-up of actions
  – Opportunity to achieve, at least improve what remains to do for the prevention and control of hepatitis in France
Impact of new treatments on HCV epidemiology in France

Prevalence: - 68,000
Mortality avoided: 8100
Cirrhoses avoided: 8200

Leleu H et al, AASLD 2013
VHPB, Antwerp Nov 14th 2014
Thank you for your attention